Supplement: 41467_2024_45594_MOESM4_ESM.xlsx › All
Molecular landscape of TP53 mutations in breast cancer and their utility for predicting the response to HER-targeted therapy in HER2 amplification-positive and HER2 mutation-positive amplification-negative patients.